Development of RNA aptamers targeting Ebola virus VP35.
暂无分享,去创建一个
Gaya K Amarasinghe | P. Luthra | Gai Liu | J. M. Binning | C. Basler | D. Leung | G. Amarasinghe | D. Borek | W. Xu | Reed S Shabman | Christopher F Basler | Priya Luthra | Gai Liu | Daisy W Leung | Dominika M Borek | Tianjiao Wang | Jennifer M Binning | Tianjiao Wang | Wei Xu
[1] W. Ian Lipkin,et al. Discovery of an Ebolavirus-Like Filovirus in Europe , 2011, PLoS pathogens.
[2] S. Nichol,et al. Ebola and marburg hemorrhagic fever. , 2010, Clinics in laboratory medicine.
[3] Z. Otwinowski,et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35 , 2010, Nature Structural &Molecular Biology.
[4] S. Zaki,et al. Inhibition of IRF-3 Activation by VP35 Is Critical for the High Level of Virulence of Ebola Virus , 2008, Journal of Virology.
[5] H. Feldmann,et al. Ebola and Marburg viruses: pathogenesis and development of countermeasures. , 2005, Current molecular medicine.
[6] A. Rein,et al. RNA Aptamers Directed to Human Immunodeficiency Virus Type 1 Gag Polyprotein Bind to the Matrix and Nucleocapsid Domains and Inhibit Virus Production , 2010, Journal of Virology.
[7] G. Nabel,et al. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. , 2002, Molecular cell.
[8] H. Feldmann,et al. Ebola haemorrhagic fever , 2011, The Lancet.
[9] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[10] V. Volchkov,et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[11] C. Lawrence,et al. RNA secondary structure prediction by centroids in a Boltzmann weighted ensemble. , 2005, RNA.
[12] J. M. Binning,et al. Basic Residues within the Ebolavirus VP35 Protein Are Required for Its Viral Polymerase Cofactor Function , 2010, Journal of Virology.
[13] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[14] J. Wilson,et al. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. , 2001, Virology.
[15] J. Sabina,et al. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. , 1999, Journal of molecular biology.
[16] Stephan Becker,et al. Comparison of the Transcription and Replication Strategies of Marburg Virus and Ebola Virus by Using Artificial Replication Systems , 1999, Journal of Virology.
[17] Vincent B. Chen,et al. Correspondence e-mail: , 2000 .
[18] H. Klenk,et al. The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3 , 2003, Journal of Virology.
[19] H. Feldmann,et al. Molecular characterization of an isolate from the 1989/90 epizootic of Ebola virus Reston among macaques imported into the United States. , 2002, Virus research.
[20] N. Sullivan,et al. Ebolavirus Proteins Suppress the Effects of Small Interfering RNA by Direct Interaction with the Mammalian RNA Interference Pathway , 2011, Journal of Virology.
[21] Yong Wang,et al. Nucleic acid aptamers for clinical diagnosis: cell detection and molecular imaging , 2011, Analytical and bioanalytical chemistry.
[22] P. Jahrling,et al. Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference , 2006, The Journal of infectious diseases.
[23] V. Volchkov,et al. Mutations Abrogating VP35 Interaction with Double-Stranded RNA Render Ebola Virus Avirulent in Guinea Pigs , 2010, Journal of Virology.
[24] N. Sullivan,et al. Ebolavirus vaccines for humans and apes. , 2012, Current opinion in virology.
[25] Yoon-Sik Lee,et al. RNA aptamers: a review of recent trends and applications. , 2013, Advances in biochemical engineering/biotechnology.
[26] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[27] Jens H. Kuhn,et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations , 2010, Archives of Virology.
[28] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[29] D. A. Stein,et al. Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers , 2006, PLoS pathogens.
[30] H. Ebihara,et al. Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. , 2013, Cell host & microbe.
[31] S. Nichol,et al. Reverse Genetic Generation of Recombinant Zaire Ebola Viruses Containing Disrupted IRF-3 Inhibitory Domains Results in Attenuated Virus Growth In Vitro and Higher Levels of IRF-3 Activation without Inhibiting Viral Transcription or Replication , 2006, Journal of Virology.
[32] J. McCaskill. The equilibrium partition function and base pair binding probabilities for RNA secondary structure , 1990, Biopolymers.
[33] C. Basler,et al. Ebolavirus VP35 is a multifunctional virulence factor. , 2010, Virulence.
[34] M. Aman,et al. Advances in virus-like particle vaccines for filoviruses. , 2011, The Journal of infectious diseases.
[35] S. Nichol,et al. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. , 2004, Virology.
[36] Virgil L. Woods,et al. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression , 2009, Proceedings of the National Academy of Sciences.
[37] Z. Otwinowski,et al. Structural basis for Marburg virus VP35–mediated immune evasion mechanisms , 2012, Proceedings of the National Academy of Sciences.
[38] J. Nix,et al. Structure of the Ebola VP35 interferon inhibitory domain , 2009, Proceedings of the National Academy of Sciences.
[39] J. Alimonti,et al. In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. , 2007, The Journal of infectious diseases.
[40] Yann Ponty,et al. VARNA: Interactive drawing and editing of the RNA secondary structure , 2009, Bioinform..
[41] Jay Painter,et al. Electronic Reprint Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion , 2005 .
[42] Randy J. Read,et al. Phenix - a comprehensive python-based system for macromolecular structure solution , 2012 .
[43] C. Basler,et al. Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. , 2010, Journal of molecular biology.
[44] Ronny Lorenz,et al. The Vienna RNA Websuite , 2008, Nucleic Acids Res..
[45] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.
[46] Joshua C. Johnson,et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.
[47] G. Nabel,et al. A Filovirus-Unique Region of Ebola Virus Nucleoprotein Confers Aberrant Migration and Mediates Its Incorporation into Virions , 2008, Journal of Virology.
[48] B. Berkhout,et al. The Ebola Virus VP35 Protein Is a Suppressor of RNA Silencing , 2007, PLoS pathogens.
[49] Andrew D Ellington,et al. Aptamer therapeutics advance. , 2006, Current opinion in chemical biology.
[50] A. Ellington,et al. In Vitro Selection of RNA Aptamers to a Protein Target by Filter Immobilization , 2000, Current protocols in molecular biology.
[51] Erica Ollmann Saphire,et al. Ebola Virus VP35 Protein Binds Double-Stranded RNA and Inhibits Alpha/Beta Interferon Production Induced by RIG-I Signaling , 2006, Journal of Virology.
[52] T. Fitzwater,et al. A SELEX primer. , 1996, Methods in enzymology.
[53] M. T. McIntosh,et al. Discovery of Swine as a Host for the Reston ebolavirus , 2009, Science.
[54] Zongdi Feng,et al. The VP35 Protein of Ebola Virus Inhibits the Antiviral Effect Mediated by Double-Stranded RNA-Dependent Protein Kinase PKR , 2006, Journal of Virology.
[55] M. Bray,et al. Filovirus research: knowledge expands to meet a growing threat. , 2007, The Journal of infectious diseases.
[56] D. A. Stein,et al. VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice , 2006, Antimicrobial Agents and Chemotherapy.
[57] D. Bunka,et al. Development of aptamer therapeutics. , 2010, Current opinion in pharmacology.
[58] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[59] G. Peters,et al. Phosphorylation of Specific Serine Residues in the PKR Activation Domain of PACT Is Essential for Its Ability to Mediate Apoptosis* , 2006, Journal of Biological Chemistry.
[60] C. Basler,et al. Ebola Virus Protein VP35 Impairs the Function of Interferon Regulatory Factor-Activating Kinases IKKε and TBK-1 , 2009, Journal of Virology.
[61] R. N. Harty,et al. Ebola Virus VP35-VP40 Interaction Is Sufficient for Packaging 3E-5E Minigenome RNA into Virus-Like Particles , 2006, Journal of Virology.
[62] P. Jahrling,et al. Towards a vaccine against Ebola virus , 2003, Expert review of vaccines.
[63] E. Mühlberger,et al. Ebola Virus VP35 Antagonizes PKR Activity through Its C-Terminal Interferon Inhibitory Domain , 2009, Journal of Virology.
[64] Emiko Suzuki,et al. Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP , 2002, Journal of Virology.
[65] Jennifer M. Binning,et al. Aptamers in Virology: Recent Advances and Challenges , 2012, Front. Microbio..
[66] P. Jahrling,et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA , 1990, The Lancet.